TARSUS PHARMACEUTICALS, INC. Increase (Decrease) in Accounts Receivable
TARSUS PHARMACEUTICALS, INC. (TARS) reported Increase (Decrease) in Accounts Receivable of $10.97 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsReceivable · last filed 2026-08-06
- TARSUS PHARMACEUTICALS, INC. increase (decrease) in accounts receivable for the quarter ending 2026-06-30 was -$19.32M.
- TARSUS PHARMACEUTICALS, INC. increase (decrease) in accounts receivable for the quarter ending 2026-03-31 was $30.29M, a 93.33% increase year-over-year.
- TARSUS PHARMACEUTICALS, INC. increase (decrease) in accounts receivable for the quarter ending 2025-12-31 was $12.44M, a 29.34% decline year-over-year.
- TARSUS PHARMACEUTICALS, INC. increase (decrease) in accounts receivable for the quarter ending 2025-09-30 was $14.29M.
- TARSUS PHARMACEUTICALS, INC. increase (decrease) in accounts receivable for fiscal 2025 was $38.30M, a 27.07% increase from fiscal 2024.
- TARSUS PHARMACEUTICALS, INC. increase (decrease) in accounts receivable for fiscal 2024 was $30.14M, a 81.33% increase from fiscal 2023.
- TARSUS PHARMACEUTICALS, INC. increase (decrease) in accounts receivable for fiscal 2023 was $16.62M.
- TARSUS PHARMACEUTICALS, INC. increase (decrease) in accounts receivable for fiscal 2022 was $0.00.
| Period end | Increase (Decrease) in Accounts Receivable 3 month | Increase (Decrease) in Accounts Receivable 6 month | Increase (Decrease) in Accounts Receivable 9 month | Increase (Decrease) in Accounts Receivable 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$19.32M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $10.97M 10-Q · filed 2026-08-06 | $23.41M derived: sum of 3 quarters · filed 2026-08-06 | $37.70M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $30.29M 10-Q · filed 2026-05-06 | $42.72M derived: sum of 2 quarters · filed 2026-05-06 | $57.01M derived: sum of 3 quarters · filed 2026-05-06 | $52.92M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $12.44M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | $26.72M derived: sum of 2 quarters · filed 2026-02-23 | $22.63M derived: sum of 3 quarters · filed 2026-08-06 | $38.30M 10-K · filed 2026-02-23 |
| 2025-09-30 | $14.29M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $10.19M derived: sum of 2 quarters · filed 2026-08-06 | $25.86M 10-Q · filed 2025-11-04 | $43.46M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | -$4.09M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $11.57M 10-Q · filed 2026-08-06 | $29.18M derived: sum of 3 quarters · filed 2026-08-06 | $28.80M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $15.67M 10-Q · filed 2026-05-06 | $33.27M derived: sum of 2 quarters · filed 2026-05-06 | $32.90M derived: sum of 3 quarters · filed 2026-05-06 | $32.54M derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | $17.60M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | $17.23M derived: sum of 2 quarters · filed 2026-02-23 | $16.88M derived: sum of 3 quarters · filed 2026-02-23 | $30.14M 10-K · filed 2026-02-23 |
| 2024-09-30 | -$370.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | -$726.00K derived: sum of 2 quarters · filed 2025-11-04 | $12.54M 10-Q · filed 2025-11-04 | $23.80M derived: sum of 4 quarters · filed 2026-02-23 |
| 2024-06-30 | -$356.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | $12.91M 10-Q · filed 2025-08-06 | $24.17M derived: sum of 3 quarters · filed 2026-02-23 | $29.53M derived: sum of 4 quarters · filed 2026-02-23 |
| 2024-03-31 | $13.26M 10-Q · filed 2025-05-01 | $24.52M derived: sum of 2 quarters · filed 2026-02-23 | $29.89M derived: sum of 3 quarters · filed 2026-02-23 | $27.39M derived: sum of 4 quarters · filed 2026-02-23 |
| 2023-12-31 | $11.26M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | $16.62M derived: sum of 2 quarters · filed 2026-02-23 | $14.12M derived: sum of 3 quarters · filed 2026-02-23 | $16.62M 10-K · filed 2026-02-23 |
| 2023-09-30 | $5.36M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | $2.86M derived: sum of 2 quarters · filed 2024-11-13 | $5.36M 10-Q · filed 2024-11-13 | $5.34M derived: sum of 4 quarters · filed 2025-02-25 |
| 2023-06-30 | -$2.50M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $0.00 10-Q · filed 2024-08-08 | -$17.00K derived: sum of 3 quarters · filed 2025-02-25 | -$17.00K derived: sum of 4 quarters · filed 2025-02-25 |
| 2023-03-31 | $2.50M 10-Q · filed 2024-05-08 | $2.48M derived: sum of 2 quarters · filed 2025-02-25 | $2.48M derived: sum of 3 quarters · filed 2025-02-25 | $2.48M derived: sum of 4 quarters · filed 2025-02-25 |
| 2022-12-31 | -$17.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-25 | -$17.00K derived: sum of 2 quarters · filed 2025-02-25 | -$17.00K derived: sum of 3 quarters · filed 2025-02-25 | $0.00 10-K · filed 2025-02-25 |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $0.00 derived: sum of 2 quarters · filed 2023-11-09 | $17.00K 10-Q · filed 2023-11-09 | |
| 2022-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | $17.00K 10-Q · filed 2023-08-10 | ||
| 2022-03-31 | $17.00K 10-Q · filed 2023-05-09 | |||
| 2021-09-30 | -$20.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | -$25.00M derived: sum of 2 quarters · filed 2022-11-09 | $0.00 10-Q · filed 2022-11-09 | |
| 2021-06-30 | -$5.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | $20.00M 10-Q · filed 2022-08-11 | ||
| 2021-03-31 | $25.00M 10-Q · filed 2022-05-11 | |||
| 2020-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05 | $0.00 10-Q · filed 2021-08-05 | ||
| 2020-03-31 | $0.00 10-Q · filed 2021-05-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |